Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Virtus LifeSci Biotech Clinical Trials ETF(BBC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BBC
10/14/2026: BBC (1-star) is currently NOT-A-BUY. Pass it for now.
The Virtus LifeSci Biotech Clinical Trials ETF (BBC) provides targeted exposure to US-listed biotechnology companies currently engaged in clinical trials, offering investors a 'pure-play' bet on drug development rather than established pharmaceutical sales. Its main strength lies in this specialized focus, which can capture significant gains from successful trial data readouts and subsequent M&A interest. However, investors must be prepared for extreme volatility and high-risk binary outcomes inherent in clinical research, as well as relatively lower liquidity and a higher expense ratio compared to broader biotech funds. It is best suited for aggressive growth investors or those performing tactical sector rotation who can monitor regulatory and trial-specific catalysts closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The fund offers direct exposure to the high-growth potential of early-stage pharmaceutical innovation. |
| Momentum investor | Strong fit while signal remains positive | Biotech stocks often exhibit strong momentum trends around major clinical trial data announcements. |
| Value investor | Weak fit | Most holdings in this fund are pre-revenue and lack traditional value metrics like P/E ratios. |
| Dividend/Income investor | Weak fit | The underlying clinical-stage biotech companies do not pay dividends. |
| Low-risk investor | Weak fit | The speculative nature of clinical trials makes this a high-volatility, high-risk investment. |
Investor Profile
Ideal Investor Profile
The ideal investor is an aggressive growth-oriented participant who understands the binary risks of drug development and seeks targeted exposure to clinical trials.
Suitability
Best for sophisticated, long-term investors looking for a niche biotech tilt; less suitable for conservative investors or those requiring daily liquidity.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Clinical-stage biotech stocks frequently experience double-digit percentage moves based on trial results. |
| Market risk | High | The biotech sector is highly susceptible to broad market downturns and shifts in risk appetite. |
| Concentration | Medium / high | The fund is limited to a specific sub-industry, increasing sensitivity to sector-specific regulatory or scientific setbacks. |
| Tracking/expense | Medium | The 0.79% expense ratio is relatively high compared to broader index-based ETFs. |
| Liquidity | Medium / high | Low trading volumes can make it difficult to enter or exit positions without impacting the price. |
| Business/sector quality | High | The underlying companies often lack consistent revenue or profit, relying heavily on capital markets for funding. |
Risk Analysis
Volatility
Extremely high; the fund is subject to binary outcomes based on clinical trial results.
Market Risk
High; the fund is exposed to biotech sector risk, regulatory risk, and broad market volatility.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Industry | Biotechnology (Clinical Stage) | 95 | This provides pure-play exposure to the inherent risks and rewards of clinical-stage drug development. |
| Cash/collateral | Cash and Cash Equivalents | 5 | Small cash reserves are held to manage daily liquidity and fund flows. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type ETF | Historic Profit 104.79% | Avg. Invested days 58 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/14/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.